Syndax Pharmaceuticals (SNDX) Profit After Tax (2015 - 2026)

Syndax Pharmaceuticals' Profit After Tax history runs 12 years deep, the most recent figure standing at -$42.7 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 49.71% year-over-year to -$42.7 million; the TTM figure through Mar 2026 stood at -$243.2 million (up 26.56% YoY), while the FY2025 annual figure was -$285.4 million, up 10.46% from the prior year.
• Profit After Tax was -$42.7 million for Q1 2026 at Syndax Pharmaceuticals, up from -$68.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$35.4 million in Q3 2022 to a low of -$94.2 million in Q4 2024.
• Historically, Profit After Tax has averaged -$59.2 million across 5 years, with a median of -$60.7 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Profit After Tax plunged 140.74% in 2022, then soared 49.71% in 2026.
• A 5-year view of Profit After Tax shows it stood at -$39.2 million in 2022, then tumbled by 84.91% to -$72.5 million in 2023, then fell by 29.94% to -$94.2 million in 2024, then climbed by 27.77% to -$68.0 million in 2025, then soared by 37.26% to -$42.7 million in 2026.
• The last three Profit After Tax figures came in at -$42.7 million (Q1 2026), -$68.0 million (Q4 2025), and -$60.7 million (Q3 2025), per Business Quant data.